Skip to main content

Generation of Improved Cellular and Animal Models for Identification of Disease Phenotype and New Therapeutic Targets of Alzheimer’s Disease


Start Date
End Date
Total Funding
€ 1 901 835
Funding Programme
European Countries Involved
The mechanisms of Alzheimer’s disease (AD) have remained poorly understood while com- mon animal models have not helped in finding efficient therapies for the disease. This pro- ject aims to generate new human cellular models allowing for the purification of specific neural cell types involved in AD. We generate patient neural cells through reprogramming patients’ skin cells, grow them alone or in mixed 3-dimensional cultures, and use them to ad- dress disease relevant mechanisms both in a dish and in animals after transplantation. Such approaches will allow for the characterization of cellular dysfunction and death pro- cesses in neurons and their supporting glia cells and will help establish whether neuroinflam- mation by glial cells truly determines the disease progression. We will substantiate our ap- proaches through the implementation of relevant stressors known to contribute to AD path- ogenesis, considering the relationships between risk (such as aging, ischemic insults, inflam- mation, oxidative stress), protective factors and genetic determinants. The usefulness of our approach will be confirmed by monitoring disease progression using innovative imaging techniques. As our AD models are based on human cells, they are clinically relevant and are expected help lead to the development of early diagnosis and the design of drugs and the application of personalized treatments for people suffering from AD.
Project partners
University of Eastern Finland
University of Lund
University of Toulouse
University of Lisbon
University Hospital of Bonn
University of Wurzburg
University of Eastern Finland
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).